Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention [3] - The company has a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing chimeric endocrine receptor-T cell (CER-T) technology [3] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - The company partners with renowned research institutions to explore emerging technologies for further development and commercialization [3] Upcoming Events - Anixa will host its 2025 Annual Meeting of Stockholders on March 20, 2025, at 10:00 a.m. Pacific Time in a virtual format [1] - Following the formal business and voting portion, Anixa's Chairman and CEO, Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a Q&A session [2] - Interested parties can access the meeting online at www.virtualshareholdermeeting.com/ANIX2025 [2]